SF3B1突变葡萄膜黑色素瘤剪接模式产生共享免疫原性肿瘤特异性新抗原
本研究探讨SF3B1突变葡萄膜黑色素瘤中剪接异常产生的新抗原。发现携带SF3B1突变肿瘤的患者中20%可检测到针对这些新抗原的记忆CD8+ T细胞,这些T细胞在血液中呈现克隆扩增并存在于肿瘤中,能特异性识别和杀伤SF3B1突变肿瘤细胞。提示剪接因子突变新抗原可作为治疗靶点。
要点
- SF3B1突变产生共享且肿瘤特异的新抗原
- 20%患者有针对新抗原的记忆CD8+ T细胞
- 新抗原特异性T细胞可杀伤SF3B1突变肿瘤细胞
核心结论
- SF3B1突变葡萄膜黑色素瘤产生的共享新抗原可被CD8+ T细胞识别并杀伤肿瘤细胞,支持其作为治疗靶点。
研究设计与样本
- 本研究为实验研究,分析了SF3B1突变葡萄膜黑色素瘤患者样本中的新抗原特异性T细胞。
主要发现
- 20%携带SF3B1突变肿瘤的葡萄膜黑色素瘤患者中优先存在针对这些新抗原的记忆CD8+ T细胞。
- 血液中新表位特异性T细胞呈现大克隆扩增,具有不同的效应转录模式。
- 部分扩增的T细胞受体也存在于相应肿瘤中。
- 新表位特异性CD8+ T细胞克隆能特异性识别并杀伤SF3B1突变肿瘤细胞。
临床怎么用
- 剪接因子突变产生的新抗原可作为共享治疗靶点,适用于多种肿瘤的免疫治疗策略开发。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Disruption of splicing patterns due to mutations of genes coding splicing factors in tumors represents a potential source of tumor neoantigens, which would be both public (shared between patients) and tumor-specific (not expressed in normal tissues). In this study, we show that mutations of the splicing factor SF3B1 in uveal melanoma generate such immunogenic neoantigens. Memory CD8+ T cells specific for these neoantigens are preferentially found in 20% of patients with uveal melanoma bearing SF3B1-mutated tumors. Single-cell analyses of neoepitope-specific T cells from the blood identified large clonal T-cell expansions, with distinct effector transcription patterns. Some of these expanded T-cell receptors are also present in the corresponding tumors. CD8+ T-cell clones specific for the neoepitopes specifically recognize and kill SF3B1-mutated tumor cells, supporting the use of this new family of neoantigens as therapeutic targets. SIGNIFICANCE: Mutations of the splicing factor SF3B1 in uveal melanoma generate shared neoantigens that are uniquely expressed by tumor cells, leading to recognition and killing by specific CD8 T cells. Mutations in splicing factors can be sources of new therapeutic strategies applicable to diverse tumors.This article is highlighted in the In This Issue feature, p. 1861.
引用
- Bigot J, Lalanne AI, Lucibello F, et al. Splicing Patterns in SF3B1-Mutated Uveal Melanoma Generate Shared Immunogenic Tumor-Specific Neoepitopes. Cancer Discov. 2021. PMID: 33811047. doi:10.1158/2159-8290.CD-20-0555
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。